Drug intelligence / Profile preview

AvantGel

Development stage: Preclinical
Lead developer: AvantGuard
Modality: Small Molecules
Administration: Topical

Overview

AvantGel is a topical antimicrobial gel developed by AvantGuard for the decolonization of *Candida auris* from the skin. The formulation is based on the Avantamine™ platform, which utilizes N-halamine (chloramine) chemistry to deliver oxidative halogen species. This mechanism of action provides broad-spectrum antimicrobial activity, effectively killing fungi and bacteria while also reducing biofilms. AvantGel is currently in the IND-enabling stage of development, with the company intending to pursue regulatory pathways such as Qualified Infectious Disease Product (QIDP) or Orphan Drug designation to address the urgent threat of multidrug-resistant pathogens in healthcare settings.

Brand names: AvantGel
Other names: Avantamine

Beyond the preview

Go deeper on AvantGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AvantGel.

Explore the full profile